Intersect ENT Announces Positive Data from Pivotal Study of Propel Implant, Showing Significantly Improved Outcomes For Sinus Surgery. September 13, 2011 01:30 PM Eastern Daylight Time.

Last month, we reported on Intersect ENT, which had obtained the FDA's ok for the Propel mometasone furoate implant that offers localized, controlled drug delivery for chronic sinusitis patients ...

At Mastercard, we drive positive change through the intersection of inclusive economic growth and climate action. Learn more about our approach to developing products, programs and partnerships that ...